- 104
- 0
- 约6.02万字
- 约 20页
- 2017-11-19 发布于福建
- 举报
NDA 21-748
Page 1
Rx Only
GLUMETZA ™
(metformin hydrochloride extended release tablets)
DESCRIPTION
GLUMETZA (metformin hydrochloride) extended release tablet is an oral antihyperglycemic
drug used in the management of type 2 diabetes. Metformin hydrochloride (N,N-
dimethylimidodicarbonimidic diamide hydrochloride) is not chemically or pharmacologically
related to any other classes of oral antihyperglycemic agents. The structural formula of
metformin hydrochloride (metformin HCl) is as shown:
Metformin HCl is a white to off-white crystalline compound with a molecular formula of
C H N •HCl and a molecular weight of 165.63. Metformin HCl is freely soluble in water and is
4 11 5
practically insoluble in acetone, ether, and chloroform. The pKa of metformin is 12.4. The pH of
a 1% aqueous solution of metformin hydrochloride is 6.68. GLUMETZA tablets are modified
release dosage forms that contain 500 mg or 1000 mg of metformin HCl. Each 500 mg tablet
contains coloring, hypromellose, magnesium stearate, microcrystalline cellulose and
polyethylene oxide. Each 1000 mg tablet contains crospovidone, dibutyl sebacate,
ethylcellulose, glyceryl behenate, polyvinyl alcohol, polyvinylpyrrolidone, and silicon dioxide.
GLUMETZA 500 and 1000 mg tablets both utilize polymer-based, oral drug delivery systems,
which allow delivery of metformin HCl to the upper gastrointestinal (GI) tract.
CLINICAL PHARMACOLOGY
Mechanism of Action
Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with
type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic
mechanisms of action are different from other classes of oral antihyperglycemic agents.
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and
improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike
sulfonylureas, metformin does not produce hypoglycemia in either pat
原创力文档

文档评论(0)